NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
18 trialsNCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT01194271 2024-06-06
Neoadjuvant Ipilimumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02113657 2024-05-24
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01804465 2021-08-18
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT01498978 2020-10-14
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00064129 2020-07-30
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed
NCT00113984 2019-12-16
Vaccine and Antibody Treatment of Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02423928 2019-10-25
CryoIT
Alden Cancer Therapy II
Phase 1 Completed
NCT02279862 2019-08-28
Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Bristol-Myers Squibb
Phase 2 Completed
NCT01832870 2017-08-24
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Prostate Oncology Specialists, Inc.
Phase 1 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT00861614 2016-09-30
Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT01057810 2016-08-18
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
Phase 3 Completed
NCT00323882 2014-08-28
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00050596 2011-06-27
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 2 Completed